CRP and rheumatoid arthritis: A recent study by Xu et al. used a combination of iguratimod (25 mg bid) with NSAIDs, i.e., celecoxib 400 mg, to treat RA patients.36 In this 12-week trial, the effect was evaluated by the vital parameters of RA, such as inflammatory markers, CRP, anti-citrullinated peptide antibodies, rheumatoid factor, and ESR.